Citigroup Inc Madrigal Pharmaceuticals, Inc. Call Options Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	BUY	$212.22 - $292.96 $10.6 Million - $14.7 Million	50,100 Added 80.03%	112,700 $23.9 Million
Q2 2024 Aug 12, 2024	BUY	$193.33 - $291.99 $12.1 Million - $18.3 Million	62,600 New	62,600 $17.5 Million
Q3 2023 Nov 09, 2023	BUY	$146.04 - $225.78 $657,180 - $1.02 Million	4,500 Added 900.0%	5,000 $730,000
Q1 2023 May 11, 2023	SELL	$231.06 - $307.08 $693,180 - $921,240	-3,000 Reduced 85.71%	500 $121,000
Q4 2022 Feb 09, 2023	BUY	$58.39 - $296.54 $204,365 - $1.04 Million	3,500 New	3,500 $1.02 Million
Q2 2022 Aug 10, 2022	BUY	$58.04 - $100.2 $1.04 Million - $1.79 Million	17,900 New	17,900 $1.28 Million

297

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.34B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.